Ottawa confirms funding for rare disease research as other questions remain
WINNIPEG — The federal government confirmed at a meeting of Canadian health ministers that it is extending a funding deal on rare disease research, while wider questions on health-care funding remain unanswered.
Federal Health Minister Marjorie Michel told her provincial and territorial counterparts at the meeting in Winnipeg that the $500 million in annual funding for the National Strategy for Drugs for Rare Diseases that was set to expire next year will now be funded on an ongoing basis.
The minister said she also reached an agreement on next steps in talks to deal with other funding issues, which includes more meetings ahead.
“The decision we all agreed on is to have our public service … start the work on what will be the next step for the next negotiation on Canada Health Transfers and other agreements.”



